ARTICLE SYNOPSIS...Pfizer broke channel resistance with good volume on the 30-minute chart, enough to reverse the short-term downtrend.
AUTHOR: Arthur HillDATE: APR 2007
ARTICLE SYNOPSIS...Shares of Pfizer, Inc., have been surging higher since mid-November 2012. Can the stock break above its previous high of 26.09 sometime between now and late January 2013?
AUTHOR: Donald W. Pendergast, Jr.DATE: DEC 2012
ARTICLE SYNOPSIS...Already in an uptrend for more than 15 months, shares of Pfizer Inc. have fired yet another buy signal.
AUTHOR: Donald W. Pendergast, Jr.DATE: OCT 2012
ARTICLE SYNOPSIS...A positive divergence sets shares of Pfizer up for a test of resistance at the 50-day exponential moving average.
AUTHOR: David PennDATE: AUG 2007
ARTICLE SYNOPSIS...Pfizer (PFE) has come off its recent peak. Is this the start of a bigger downleg or just a normal correction?
AUTHOR: Gary GrosschadlDATE: JAN 2004
ARTICLE SYNOPSIS...Here's a short-term outlook to Pfizer, using short-term indicators.
AUTHOR: Koos van der MerweDATE: JAN 2005
ARTICLE SYNOPSIS...Pfizer shares may be ready to move lower still, based on the trend dynamics on its daily and weekly charts.
AUTHOR: Donald W. Pendergast, Jr.DATE: MAY 2010
ARTICLE SYNOPSIS...The bearish phase of Pfizer is likely to end.
AUTHOR: Chaitali MohileDATE: JAN 2012
ARTICLE SYNOPSIS...Pfizer shares may be on the verge of a larger, more sustained downtrend over the next few weeks.
AUTHOR: Donald W. Pendergast, Jr.DATE: JUL 2011
ARTICLE SYNOPSIS...This statistical analysis shows Pfizer is now entering into a long-term bear market trend.
AUTHOR: Alan R. NorthamDATE: OCT 2011
ARTICLE SYNOPSIS...The bears are ready to engulf the bullish rally of Pfizer.
AUTHOR: Chaitali MohileDATE: AUG 2011
ARTICLE SYNOPSIS...Pfizer has been underperforming for many years. But now there are signs the stock could see a bullish makeover.
AUTHOR: Chaitali MohileDATE: APR 2011
ARTICLE SYNOPSIS...Statistical analysis is used to show that Pfizer is in the process of reversing its intermediate-term trend from up to down.
AUTHOR: Alan R. NorthamDATE: MAR 2012
ARTICLE SYNOPSIS...Statistical analysis shows Pfizer in the process of turning down.
ARTICLE SYNOPSIS...With the Obama health plan coming into play in spite of opposition, is it worthwhile to invest in pharmaceutical companies?
AUTHOR: Koos van der MerweDATE: JAN 2011
ARTICLE SYNOPSIS...A small range-bound rally may complete the cup with handle pattern. The bullish breakout of the pattern may attract new traders.
AUTHOR: Chaitali MohileDATE: SEP 2008
ARTICLE SYNOPSIS...After being plagued by drug problems in 2004, Pfizer rebounded throughout 2005. However, bearish candlesticks and waning momentum suggest an end to the current rally.
AUTHOR: Arthur HillDATE: JUN 2005
ARTICLE SYNOPSIS...Pfizer Inc. is an established downtrend. Has its recent upside correction put it in a position to short?
AUTHOR: James KupferDATE: JUL 2008
ARTICLE SYNOPSIS...The stock is testing the lower trendline of a channel that contains prices during the past months' downtrend.
AUTHOR: Paolo PezzuttiDATE: MAY 2006
ARTICLE SYNOPSIS...The volatility has turned wild as this stock started to trade in a narrower range, experiencing choppy trading sessions.
AUTHOR: Chaitali MohileDATE: FEB 2008
ARTICLE SYNOPSIS...Pfizer is a pharmaceutical company headquartered in New York City.
AUTHOR: Koos van der MerweDATE: JUN 2017
ARTICLE SYNOPSIS...Prices could continue to move up and close the gap in the $24 area.
AUTHOR: Paolo PezzuttiDATE: DEC 2005
ARTICLE SYNOPSIS...Drug companies have suddenly decided to bare their souls, and those of their drugs. Will they bounce back, and is the risk worth taking?
DEPARTMENTS: Advertising | Editorial | Circulation | Contact
Us | BY PHONE: (206) 938-0570
PTSK — The
Professional Traders' Starter Kit
Home — S&C
Magazine | Working
Money Magazine | Traders.com
Advantage | Online Store | Traders’ Resource
Add a Product
to Traders’ Resource | Message
Boards | Subscribe/Renew | Free
Trial Issue | Article
Code | Search
Copyright © 1982–2018 Technical Analysis, Inc. All rights
reserved. Read our disclaimer & privacy